Recruitment was stopped after a preplanned interim futility analysis. Treatment was discontinued. Median disease free survival was 43.4 months (95% CI, 37.4 months to not estimable) in the afatinib group and not estimable (95% CI, 40.1 months to not estimable) in the placebo group (hazard ratio, 1.13; 95% CI, 0.81-1.57, pā=ā0.48). The most common grade 3 drug-related adverse effects were acneiform rash (61/411 afatinib group vs. 1/206 in placebo group).